Association between seven common OPG genetic polymorphisms and osteoporosis risk: A meta-analysis

DNA and Cell Biology

Volumn 33, Issue 1, 2014, Pages 29-39

  Guo, Liang ^a   Tang, Ke ^a   Quan, Zhengxue ^a   Zhao, Zenghui ^a   Jiang, Dianming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ALLELE; ARTICLE; CAUCASIAN; COCHRANE LIBRARY; EMBASE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; HUMAN; MEDLINE; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EID: 84891724207     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2206     Document Type: Article

References (39)

1. Brambila-Tapia, A.J., Duran-Gonzalez, J., Sandoval-Ramirez, L., Mena, J.P., Salazar-Paramo, M., Gamez-Nava, J.I., et al. (2012). MTHFR C677T, MTHFR A1298C, and OPG A163G polymorphisms in Mexican patients with rheumatoid arthritis and osteoporosis. Dis Markers 32, 109-114.
2. Chung, H.W., Seo, J.S., Hur, S.E., Kim, H.L., Kim, J.Y., Jung, J.H., et al. (2003). Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women. J Hum Genet 48, 243-248. (Pubitemid 36759487)
3. Cortet, B. (2011). Bone repair in osteoporotic bone: postmenopausal and cortisone-induced osteoporosis. Osteoporosis Int 22, 2007-2010.
4. Dincel, E., Sepici-Dincel, A., Sepici, V., Ozsoy, H., and Sepici, B. (2008). Hip fracture risk and different gene polymorphisms in the Turkish population. Clinics (Sao Paulo) 63, 645-650.
5. Dougall, W.C. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18, 326-335.
6. Gennari, L., Merlotti, D., De Paola, V., Calabro, A., Becherini, L., Martini, G., et al. (2005). Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol 161, 307-320. (Pubitemid 40256202)
7. Higgins, J.P., and Thompson, S.G. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539-1558. (Pubitemid 34746062)
8. Hong, X., Hsu, Y.H., Terwedow, H., Tang, G., Liu, X., Jiang, S., et al. (2007). Association of the methylenetetrahydrofolate reductase C677T polymorphism and fracture risk in Chinese postmenopausal women. Bone 40, 737-742. (Pubitemid 46187215)
9. Honma, N., Mori, S., Zhou, H., Ikeda, S., Mieno, M.N., Tanaka, N., et al. (2013). Association between estrogen receptor-beta dinucleotide repeat polymorphism and incidence of femoral fracture. J Bone Miner Metab 31, 96-101.
10. Hsu, Y.H., Niu, T., Terwedow, H.A., Xu, X., Feng, Y., Li, Z., et al. (2006). Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet 118, 568-577. (Pubitemid 41825129)
11. Hussien, Y.M., Shehata, A., Karam, R.A., Alzahrani, S.S., Magdy, H., and El-Shafey, A.M. (2013). Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis. Mol Biol Rep 40, 3675-3680.
12. Jackson, D., White, I.R., and Riley, R.D. (2012). Quantifying the impact of between-study heterogeneity in multivariate metaanalyses. Stat Med 31, 3805-3820.
13. Jin, H., van't Hof, R.J., Albagha, O.M., and Ralston, S.H. (2009). Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. Hum Mol Genet 18, 2729-2738.
14. Kim, J.G., Kim, J.H., Kim, J.Y., Ku, S.Y., Jee, B.C., Suh, C.S., et al. (2007). Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14, 913-918. (Pubitemid 47517592)
15. Kim, J.G., Ku, S.Y., Kim, H., Chun, S.W., Suh, C.S., and Choi, Y.M. (2009). Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy. Menopause 16, 534-538.
16. Kurt, O., Yilmaz-Aydogan, H., Uyar, M., Isbir, T., Seyhan, M.F., and Can, A. (2012). Evaluation of ERalpha and VDR gene polymorphisms in relation to bone mineral density in Turkish postmenopausal women. Mol Biol Rep 39, 6723-6730.
17. Langdahl, B.L., Carstens,M., Stenkjaer, L., and Eriksen, E.F. (2002). Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 17, 1245-1255. (Pubitemid 34680501)
18. Lau, H.H., Ho, A.Y., Luk, K.D., and Kung, A.W. (2004). Transforming growth factor-beta1 gene polymorphisms and bone turnover, bone mineral density and fracture risk in southern Chinese women. Calcif Tissue Int 74, 516-521. (Pubitemid 38780287)
19. Lee, Y.H., Woo, J.H., Choi, S.J., Ji, J.D., and Song, G.G. (2010). Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37, 227-234.
20. Li, X.R. (2009). [Association between OPG genetic polymorphisms and osteoporosis in elderly men]. Shandong Med J 49, 71-72.
21. Little, J., Higgins, J.P., Ioannidis, J.P., Moher, D., Gagnon, F., von Elm, E., et al. (2009). Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 125, 131-151.
22. Liu, J., Miao, Y.D., Zhang, Y.J., He, P.Y., Bao, H., Zhu, L., et al. (2010). [The study of the association between T950C gene polymorphism in the promoter region of osteoprotegerin and bone mineral density in postmenopausal women]. Chin J Osteoporos 16, 184-187.
23. McClean, E., Archbold, G.P., and Taggart, H.M. (2003). Do the COL1A1 and Taq 1 vitamin D receptor polymorphisms have a role in identifying individuals at risk of developing osteoporosis Ulster Med J 72, 26-33. (Pubitemid 36834084)
24. Mencej-Bedrac, S., Prezelj, J., Kocjan, T., Teskac, K., Ostanek, B., Smelcer, M., et al. (2009). The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J Mol Endocrinol 42, 239-247.
25. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 339, b2535.
26. Origa, R., Fiumana, E., Gamberini, M.R., Armari, S., Mottes, M., Sangalli, A., et al. (2005). Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann N Y Acad Sci 1054, 451-456. (Pubitemid 43031055)
27. Peters, J.L., Sutton, A.J., Jones, D.R., Abrams, K.R., and Rushton, L. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295, 676-680. (Pubitemid 43209069)
28. Raggatt, L.J., and Partridge, N.C. (2010). Cellular and molecular mechanisms of bone remodeling. J Biol Chem 285, 25103-25108.
29. Ralston, S.H., and de Crombrugghe, B. (2006). Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20, 2492-2506. (Pubitemid 44396835)
30. Rubin, C.D. (2005). Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21, 1049-1056. (Pubitemid 41032694)
31. Schnatz, P.F. (2011). The 2010 North American Menopause Society position statement: updates on screening, prevention and management of postmenopausal osteoporosis. Conn Med 75, 485-487.
32. Seremak-Mrozikiewicz, A., Tatusko, J., Drews, K., Barlik, M., Krajewski, P., Spaczynski, M., et al. (2009). [Polymorphism of osteoprotegerin gene and osteoporosis in postmenopausal women]. Ginekol Pol 80, 354-360.
33. Shui, M.M., Na, S.P., Xie, R.J., Wang, M.G., and Mu, S.H. (2008). [Relationship between the polymorphisms of T149C and T950C in osteoprotegerin gene and the glucocorticoid-induced osteoporosis]. Chin J Blood Purif 17, 375-379.
34. Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603-605.
35. Trouvin, A.P., and Goeb, V. (2010). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5, 345-354.
36. Vidal, C., Formosa, R., and Xuereb-Anastasi, A. (2011). Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density. J Mol Endocrinol 47, 327-333.
37. Wang, C., Zhang, Z., Zhang, H., He, J.W., Gu, J.M., Hu, W.W., et al. (2012). Susceptibility genes for osteoporotic fracture in postmenopausal Chinese women. J Bone Miner Res 27, 2582-2591.
38. Wu, Z.Z., and Liu, M. (2006). [The effect of low-body weight combined with T149C and A163G polymorphism of osteoprotegerin promoter region on osteoporosis]. Chin J Geriatrics 25, 645-650.
39. Zhao, H.Y., Liu, J.M., Ning, G., Zhao, Y.J., Zhang, L.Z., Sun, L.H., et al. (2005). The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporosis Int 16, 1519-1524 (Pubitemid 41790855)